Discontinued — last reported Q4 '25
West Pharmaceutical Services Deferred Compensation Liability (Non-Current) decreased by 12.6% to $11.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.5%, from $11.40M to $11.80M. Over 5 years (FY 2020 to FY 2025), Deferred Compensation Liability (Non-Current) shows a downward trend with a -10.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Growth in this metric indicates increasing long-term employee benefit accruals or changes in executive compensation structures.
This captures the obligation to pay employees or executives for services rendered, where payment is deferred beyond the...
Standard across large-cap corporations with significant executive and long-term incentive plans.
deferred_compensation_liability_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.70M | $26.90M | $28.90M | $26.30M | $21.40M | $19.20M | $19.10M | $19.00M | $20.60M | $17.90M | $18.60M | $18.60M | $15.50M | $15.20M | $15.40M | $11.40M | $12.50M | $13.50M | $13.50M | $11.80M |
| QoQ Change | — | +8.9% | +7.4% | -9.0% | -18.6% | -10.3% | -0.5% | -0.5% | +8.4% | -13.1% | +3.9% | +0.0% | -16.7% | -1.9% | +1.3% | -26.0% | +9.6% | +8.0% | +0.0% | -12.6% |
| YoY Change | — | — | — | — | -13.4% | -28.6% | -33.9% | -27.8% | -3.7% | -6.8% | -2.6% | -2.1% | -24.8% | -15.1% | -17.2% | -38.7% | -19.4% | -11.2% | -12.3% | +3.5% |